TE
Teva
TEVA · NYSE
$36.77 +1.13% (+$0.41)
1M +0.61%
Market Cap $42.3B
P/E Ratio 59.92x
Div. Yield -
ROE 9.07%
Bulios Fair Price
$22.53
38.7% downside
Current Price
$36.77
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TEVA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
7/9Valuation
28 /100
Expensive P/E 59.92x
EV/EBITDA 21.41x
P/S 2.44x
Growth
40 /100
Stable Rev. growth 4.96%
FCF growth 3.28%
Book val. growth 0.45%
Profitability
57 /100
Moderate Gross margin 52.47%
Net margin 4.08%
Op. margin 11.45%
Quality
35 /100
Average ROIC 6.79%
ROE 9.07%
ROA 1.77%
Debt
15 /100
High Debt/Equity 2.18x
Current ratio 0.88x
Int. coverage 1.78x
Stability
58 /100
Moderate Beta 0.87x
Rev. volatility 1.04%
EPS volatility 192.14%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TEVA
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Richard D. Francis
Employees
32,008
Headquarters
Tel Aviv
Upcoming events
04 NOV
Earnings
Upcoming earnings report